Skip to main content
RYTM
NASDAQ Life Sciences

Rhythm Q2 Revenue Jumps 19% to $71.3M on Acquired HO Launch; Cash Runway Extended

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$105.78
Mkt Cap
$7.256B
52W Low
$74.5
52W High
$122.2
52W Position info
42% above low
Off High info
13% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

RYTM sits 42% above its 52-week low of $74.5 on elevated volume (2.0× avg).

Summary

Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3 million, a 19% sequential increase fueled by the U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company disclosed multiple executive 10b5-1 trading plans and a severance agreement for its CHRO.


Key Events · Earnings and Guidance · RYTM

  • Q2 Revenue Hits $71.3M

    Net product revenue grew 19% sequentially to $71.3 million, driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity. U.S. revenue alone jumped 38% quarter-over-quarter to $51.0 million.

  • Strong Launch Metrics

    Over 400 patient start forms were received from approximately 300 prescribers since the March 2026 FDA approval, indicating robust early demand for the new indication.

  • Cash Runway Extended

    Cash and short-term investments totaled $330.9 million as of June 30, 2026, which management expects to fund operations for at least 24 months.

  • Executive 10b5-1 Trading Plans

    CEO David Meeker adopted a plan to sell up to 300,000 shares; CFO Hunter Smith, EVP Yann Mazzabraud, CSO Alastair Garfield, and EVP Jennifer Lee also adopted plans. Director Lynn Tetrault terminated a prior plan.


Analysis · RYTM · Life Sciences

Rhythm's Q2 2026 results show a sharp revenue acceleration driven by the recent U.S. launch of IMCIVREE for acquired hypothalamic obesity. Product revenue of $71.3 million grew 19% sequentially, with U.S. sales surging 38% quarter-over-quarter. The company received over 400 patient start forms from ~300 prescribers since the March 2026 FDA approval, signaling strong early demand. Operating loss widened to $48.6 million as SG&A spending ramped to support the launch, but the $330.9 million cash position is sufficient for at least 24 months. The filing also discloses multiple executive 10b5-1 trading plans, including the CEO's plan to sell up to 300,000 shares, and a severance agreement for the Chief Human Resources Officer. These insider sales plans, while pre-arranged, add a layer of caution alongside the strong commercial momentum.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RYTM was trading at $105.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $74.50 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RYTM - Latest Insights

RYTM
Nov 16, 2026, 4:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $107.31
Real-time Price: $116.92 info
Change: +$9.61 (+9%) info
Market Cap: $8.098B info
RYTM
Nov 06, 2026, 11:06 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $109.39
Real-time Price: $116.92 info
Change: +$7.53 (+7%) info
Market Cap: $8.098B info
RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $116.92 info
Change: +$7.17 (+7%) info
Market Cap: $8.098B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $116.92 info
Change: +$21.71 (+23%) info
Market Cap: $8.098B info
RYTM
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.70
Real-time Price: $116.92 info
Change: +$31.22 (+36%) info
Market Cap: $8.098B info